Zacks Investment Research upgraded shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) from a sell rating to a hold rating in a research note published on Monday.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Several other research firms have also commented on AIMT. Wedbush restated an outperform rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a report on Monday, June 13th. Piper Jaffray Cos. reaffirmed an overweight rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Tuesday, June 14th. Finally, Credit Suisse Group AG reissued a buy rating and set a $35.00 target price on shares of Aimmune Therapeutics in a research report on Friday, August 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $32.75.

Aimmune Therapeutics (NASDAQ:AIMT) opened at 15.62 on Monday. The company has a 50-day moving average of $14.31 and a 200-day moving average of $13.63. Aimmune Therapeutics has a 1-year low of $9.77 and a 1-year high of $26.50. The stock’s market capitalization is $660.01 million.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.01. Analysts anticipate that Aimmune Therapeutics will post ($1.71) earnings per share for the current fiscal year.

In other Aimmune Therapeutics news, insider Mary M. Rozenman sold 30,000 shares of Aimmune Therapeutics stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $16.80, for a total transaction of $504,000.00. Following the completion of the sale, the insider now directly owns 30,000 shares in the company, valued at approximately $504,000. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 24.56% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in shares of Aimmune Therapeutics by 150.5% in the second quarter. JPMorgan Chase & Co. now owns 105,975 shares of the company’s stock valued at $1,147,000 after buying an additional 63,675 shares during the last quarter. Emerald Acquisition Ltd. bought a new position in Aimmune Therapeutics during the second quarter worth $154,000. Swiss National Bank boosted its position in Aimmune Therapeutics by 41.3% in the second quarter. Swiss National Bank now owns 31,474 shares of the company’s stock worth $341,000 after buying an additional 9,200 shares in the last quarter. California State Teachers Retirement System boosted its position in Aimmune Therapeutics by 133.9% in the second quarter. California State Teachers Retirement System now owns 55,115 shares of the company’s stock worth $596,000 after buying an additional 31,555 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Aimmune Therapeutics by 60.8% in the second quarter. Bank of New York Mellon Corp now owns 82,661 shares of the company’s stock worth $895,000 after buying an additional 31,245 shares in the last quarter. Institutional investors and hedge funds own 68.87% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.